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Abstract 
Kidney transplantation is the treatment of choice in patients with end stage renal disease. During kidney transplanta-
tion ischemia reperfusion injury (IRI) occurs, which is a risk factor for acute kidney injury, delayed graft function and 
acute and chronic rejection. Kidneys from living donors show a superior short- and long-term graft survival compared 
with deceased donors. However, the shortage of donor kidneys has resulted in expansion of the donor pool by using 
not only living- and brain death donors but also kidneys from donation after circulatory death and from extended 
criteria donors. These grafts are associated with an increased sensitivity to IRI and decreased graft outcome due to 
prolonged ischemia and donor comorbidity. Therefore, preventing or ameliorating IRI may improve graft survival. 
Animal experiments focus on understanding the mechanism behind IRI and try to find methods to minimize IRI either 
before, during or after ischemia. This review evaluates the different experimental strategies that have been investi-
gated to prevent or ameliorate renal IRI. In addition, we review the current state of translation to the clinical setting. 
Experimental research has contributed to the development of strategies to prevent or ameliorate IRI, but promising 
results in animal studies have not yet been successfully translated to clinical use.
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Background
Kidney transplantation is the treatment of choice in 
patients with end stage renal disease. Increased preva-
lence of end stage renal disease, and improved results 
after kidney transplantation have contributed to the 
increased shortage of donor organs and the need to 
expand the donor pool [1, 2]. Organs from living donors 
have a superior graft survival compared with deceased 
donors [3, 4]. The superior outcome of living donors kid-
neys is associated with shorter warm and cold ischemia, 
shorter waiting time for the recipient and ‘healthier’ 
donor kidneys [5]. Warm ischemia occurs after the 
blood supply has been cut off while the organ is still in 
the donor. During storage of the transplant, the tempera-
ture is reduced to approximately 4  °C. During this cold 
ischemia period, metabolism is significantly reduced 
which allows for prolonged preservation of the organ 
until transplantation.
To bridge the growing gap between organ demand and 
supply, donation after circulatory death (DCD) donors 
[6] and extended criteria donors are increasingly being 
used [3–5]. Donation after brain death (DBD) donors 
are exposed to physiological changes during brain death, 
which may lead to organ damage and inferior graft sur-
vival compared to living donors [7, 8]. DCD donors do 
not develop the physiological changes of DBD donors, 
but suffer from prolonged warm ischemia times during 
cardiac arrest. DCD kidneys have an increased incidence 
of delayed graft function (DGF) of 73  % compared to 
27  % in DBD donor kidneys [9], while the rate of acute 
rejection is similar in both. Despite the higher incidence 
of DGF, DCD kidneys show no differences in long-term 
graft survival compared with DBD kidneys [6, 10].
Although the use of DCD donors has been increased, 
the total number of cadaveric donors remains stable, 
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the number of extended criteria donors is increas-
ing. Extended criteria donors are defined as donors 
being >60 years old, or aged >50–59 years old with ≥2 of 
the following risk factors: history of hypertension, serum 
creatinine level  ≥1.5  mg/dL, or death resulting from a 
cerebrovascular accident [12, 13]. Organs from extended 
criteria donors are associated with a higher incidence 
of DGF, lower graft survival and suboptimal kidney 
function [13, 14]. Recipients of kidneys procured from 
extended criteria donors show a 1.7-fold greater risk of 
graft lost compared to recipients with a kidney from an 
‘ideal donor’ (10–39  years old without hypertension or 
stroke as a cause of death and a serum creatinine concen-
tration <1.5 mg/dL) [15].
Ischemia reperfusion injury (IRI) is an inevitable con-
sequence of kidney transplantation and has major conse-
quences for graft- and patient survival [16–18]. Renal IRI 
is a known risk factor for DGF [19], acute kidney injury 
[20] and acute and chronic rejection [21]. Donor type 
is strongly associated with the severity of renal IRI [22]. 
DCD donors and extended criteria donors are more vul-
nerable to IRI since donor kidneys suffer from prolonged 
warm ischemia time, increased donor age or comor-
bidity of the donor [13, 14]. Prevention or reduction of 
IRI could improve graft survival and decrease patient 
morbidity.
Renal ischemia reperfusion injury
Renal IRI is unavoidable during transplantation and is 
a risk factor for DGF [19], acute kidney injury [18, 23] 
and acute and chronic rejection [24, 25]. Acute kidney 
injury is associated with high morbidity, prolonged 
hospitalization, and increased mortality [20, 26]. Dur-
ing ischemia there is a lack of O2 and nutrients, which 
results in a decrease of oxidative metabolism, accumu-
lation of metabolic waste products and depletion of 
ATP [19, 20].
Reperfusion leads to rewarming, reoxygenation and a 
return to aerobic metabolism. However, reactive oxygen 
species are generated which directly injure the cytoskel-
etal and functional cellular components [19]. Normally, 
antioxidant enzymes may counteract the effects of reac-
tive oxygen species, but their protective effect is over-
whelmed by the rapid production of reactive oxygen 
species, resulting in tissue injury and cell death [27].
During reperfusion, tissue injury is exacerbated by 
an inflammatory response, which initiates a cascade of 
deleterious cellular responses [18, 19]. Inflammatory 
cytokines are up regulated, and chemokines and com-
plement are released, which results in the migration and 
activation of leukocytes.
The mechanism underlying IRI is multifactorial. Due to 
its complexity, IRI provides different targets to prevent or 
ameliorate renal IRI before, during or after transplanta-
tion [23].
Strategies to ameliorate renal IRI
Strategies to reduce renal IRI can be implemented in 
both donor and recipient, and before, during and after 
transplantation. Treatment of IRI can be focused on 
scavenging reactive oxygen species, reducing inflam-
mation, stimulating cell survival and regeneration, or a 
combination thereof. Prevention of ischemia is impossi-
ble by inducing resistance against ischemia before organ 
retrieval. Pre-treatment of living donors is feasible, pro-
vided it does not affect the health and wellbeing of the 
donor. In post-mortem donors the situation is more dif-
ficult since these donors are not able to give informed 
consent and ethical issues may rise. During preservation 
treatment is possible by using machine preservation and/
or by adding protective agents to the perfusion fluid, 
pre- or post-conditioning is feasible during transplanta-
tion. After transplantation, treating the recipient, after 
informed consent, may reduce the damage caused by IRI.
In this review, we focus on experimental and clini-
cal studies on dietary preconditioning, preservation, 
ischemic pre- and post-conditioning, cell therapy, phar-
macological treatment and microRNAs as intervention 
strategies to reduce renal IRI. In addition, we review the 
current state of translation to the clinical setting of these 
interventions (Fig. 1).
Dietary preconditioning
Dietary restriction is a reduction in food intake without 
malnutrition, and is associated with extended life span, 
improved metabolic fitness and increased resistance to 
oxidative stress in a wide range of organisms [28–30]. 
In mice, short-term 30  % dietary restriction or 3  days 
of fasting, reduced kidney damage and dysfunction and 
improved survival after renal IRI [30]. Short-term dietary 
restriction and fasting increased expression of cytopro-
tective genes and decreased the expression of inflamma-
tory markers [30]. Food restriction leads to a reduction 
in both calorie and nutrient intake, yet the contribution 
of calories or nutrients to the protective effect on renal 
IRI is unknown [28]. Verweij et  al. [31] showed that 
the benefits of preoperative fasting are not affected by 
the intake of calories via glucose water during fasting 
from solid food. Subsequently, diets lacking protein or 
even the essential amino acid tryptophan for 6–14 days 
resulted in similar protection against renal IRI in mice 
[32–34]. Therefore, a preoperative calorie restricted diet 
might be a non-invasive way to reduce IRI after human 
kidney transplantation. Although the beneficial effects 
of a preoperative diet are in apparent conflict with the 
patients’ nutritional wellbeing [35, 36], several recent 
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clinical studies showed that the human response to die-
tary restriction is similar to that observed in experimen-
tal mammalian models [37, 38].
In human living kidney donors short-term dietary 
restriction before surgery is feasible, well tolerated and 
safe [39], although the conditions to induce a similar 
powerful protection against IRI as in mice have not been 
elucidated yet. More clinical research is needed to trans-
late the beneficial effect of preoperative diets from ani-
mals to humans.
Preservation
Another option to decrease IRI is to minimize damage 
caused during ischemia. Prolonged cold ischemia time 
has a strong association with development of DGF [19, 
25], but a decrease in cold ischemia time is difficult due 
to logistics, allocation and organ transport. Optimisa-
tion of conditions during cold ischemia time is there-
fore essential. Cold storage solutions were designed to 
increase organ tolerance and preserve cellular integrity 
during ischemia [40, 41]. Reducing the temperature of 
the kidney to 4  °C reduces enzyme activity, decreases 
oxygen requirement and lowers metabolism by 58 % [42]. 
Some studies add nutrients or pharmacologically active 
agents to the preservation solution (reviewed in [43]). 
Cold storage is still considered the gold standard in kid-
ney preservation.
During machine perfusion, the organ is attached to a 
machine during preservation, which pumps preserva-
tion solution through the organ. It creates the possibil-
ity to maintain hemodynamic stimulation, administer 
nutrients to the kidney and even eliminate toxins. A large 
international prospective randomized controlled trial 
The Netherlands showed the benefits of machine perfu-
sion by reducing the incidence and duration of DGF, in 
DCD kidneys [44]. Also, machine perfusion of extended 
criteria donor kidneys reduced the rate of DGF [45, 46], 
is feasible, and safe [47]. In a meta-analysis, Deng et  al. 
[48] compared the transplant outcomes in patients 
receiving DCD kidneys preserved by machine perfusion 
or by static cold storage. Recipients with a DCD kidney 
preserved by machine perfusion had a decreased inci-
dence of DGF compared to static cold storage. However, 
there is no significant difference between the two groups 
in incidence of primary non-function, graft survival or 
patient survival after 1 year.
Hypothermic machine preservation slows down the 
metabolism of the kidney and allows an organ to be 
stored without oxygen for a short period of time but this 
process also causes cellular damage. Therapeutic agents 
have been added to the preservation solution during 
hypothermic machine preservation but the hypother-
mic conditions make it difficult for the agent while the 
metabolism is blocked. Maintaining the kidney at a nor-
mothermic temperature has many advantages. The kid-
ney is able to regain function and can minimize the cold 
ischemia time. The kidney can be maintained in a stable 
state and it provides the opportunity to add therapeuti-
cal agents to a functioning organ [49]. Machine perfusion 
is one of the therapeutic interventions that is making the 
translation to humans. Randomized controlled trials are 
now being developed and will guide machine perfusion 
into the clinical arena.
Ischemic pre‑/post‑conditioning
Ischemic conditioning is defined as applying a brief 
ischemic insult to an organ through brief (repetitive) 
sequences of ischemia and reperfusion before or after 
an ischemic attack to provide resistance against IRI. 
Ischemic preconditioning (IPC) and ischemic post-con-
ditioning (IPoC) were both developed in cardiac research, 
but may be applied in the kidney as well, reviewed in [50].
Renal IRI
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Fig. 1 Overview of various therapies before, during and after kidney transplantation, which are capable of ameliorating renal ischemia reperfusion 
injury in animal models
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Ischemic pre‑conditioning
In 1986, protection against IRI by IPC was first seen in 
canine hearts [51]. Dogs were preconditioned with four 
repetitive sequences of ischemia and reperfusion each 
5  min, followed by 40  min of occlusion. IPC limited 
infarct size to 25 % compared to the control group. After 
these findings many animal experiments have been done 
to reproduce this protective effect in other organs [52]. 
In the kidney, IPC induces improved renal function and 
histology after transplantation [53].
In remote IPC, the ischemic trigger is not applied 
locally to the target organ, but on another ‘remote’ organ 
[54]. Patients undergoing elective coronary artery bypass 
graft surgery underwent remote IPC consisting of three 
5-minute cycles of right upper limb ischemia directly 
after anesthesia. Remote IPC reduced serum troponin-T 
release compared to patients undergoing coronary artery 
bypass graft surgery without IPC [55].
In a rat model, renal IRI was induced by a right 
nephrectomy and clamping the left renal artery for 
60 min. Remote IPC was induced by 5-minute cycles of 
ischemia and reperfusion, occluding the right hind limb. 
The remote IPC groups showed lower levels of kidney 
dysfunction and damage [56]. In a renal IRI pig model, 
remote IPC was induced by clamping the left iliac artery 
for 10 min, which showed no beneficial effects on renal 
function or histology [57]. In humans, kidney transplant 
recipients underwent remote IPC and were compared to 
paired recipients without IPC. Remote IPC was induced 
by three cycles of 5  min of brief repetitive ischemia by 
clamping the exposed external iliac artery. Serum cre-
atinine levels were lower in the remote IPC group, 
while glomerular filtration rates were higher during the 
first 14  days post-transplant. These results suggest that 
remote IPC has beneficial effects on the early recovery of 
renal function after kidney transplantation [58].
Remote preconditioning is a potential therapeutic 
strategy that can reduce renal IRI, and is simple to apply, 
non-invasive and virtually cost-free, but large multi-
center clinical trials using remote IPC are needed to 
improve the level of evidence and implement remote IPC 
in the clinical setting. Results of a large international pro-
spective randomized controlled trial (CONTEXT trial) 
are eagerly awaited [59].
Ischemic post‑conditioning
IPoC, defined as rapid, intermittent interruptions of 
blood flow at the onset of reperfusion can reduce myo-
cardial infarct size in animal models [60, 61]. The use 
of IPoC in humans undergoing cardiac surgery showed 
better post-operative outcomes [62]. Similar benefi-
cial effects have also been observed in animal models 
of renal IRI [63]. IPoC reduced tubular necrosis after 
reperfusion, and attenuated renal dysfunction [64]. 
Its observed benefits are associated with an enhanced 
expression level of SOD and inhibition of apoptosis 
[65]. These effects are seen in different animal species 
with different index ischemia times and different algo-
rithms. Only two studies did not observe a significant 
difference in renal function, which could be explained 
by the time points of analyzing renal function which 
were either too early (2  h) or too late (12  weeks) after 
reperfusion [66, 67].
Contrary to IPoC, remote IPoc has only been per-
formed in two renal IRI rat studies [56, 68]. Remote IPoC 
of the hind limb resulted in significant improvement in 
renal function 24 h after IRI. Sequences of ischemia and 
reperfusion during the ischemic episode, PER-condi-
tioning, was able to reduce renal IRI even further [68]. 
As with IPC, the first attempts to translate IPoC into 
human kidney transplantation are already being done 
[69]. Unfortunately, the robust beneficial effects as seen 
in animal experiments, have not been observed yet. IPoC 
is feasible and safe in patients undergoing kidney trans-
plantation, but the proper algorithm that reduces the 
incidence of DGF still has to be found [69].
Cellular therapy
Administration of cells to modulate the course of IRI has 
attracted considerable interest. Two cell types in particu-
lar, mesenchymal stem cells (MSC), and regulatory T 
cells (Tregs) have been investigated.
Mesenchymal stem cells (MSCs) are able to differen-
tiate into cell types other than their tissue of origin, are 
non-immunogenic, immunosuppressive, able to migrate, 
secrete growth factors and anti-apoptotic cytokines 
[70], and might play a role in tissue repair. Due to these 
characteristics, MSCs are promising as a cell therapy to 
reduce renal IRI. In rodent renal IRI models, MSCs were 
able to upregulate the cytoprotective genes HO-1 and 
SOD [71–73], reduce oxidative stress and apoptosis [71], 
and improve kidney function [71, 72, 74]. Furthermore, 
kidneys treated with MSCs showed a stronger regenera-
tive response [75].
Subsequently, in large-animal models, MSCs failed 
to reduce cell death and no changes in proliferation or 
cytokine release were found [76, 77]. It might be that the 
optimal time window for stem cell therapy is different in 
large-animal models than in rodents. Another problem 
is poor cell survival of injected MSCs. After intravenous 
injection MSCs home to the lungs and within 24  h the 
majority of MSCs die, MSCs do not migrate to the site 
of injury and do not contribute to structural renal repair 
[78]. This suggests that the effect of the MSCs might 
result from paracrine or endocrine effects unrelated to 
their differentiation capacity [78–82].
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Early clinical trials have attempted to translate the 
potential immunosuppressive effects of MSCs, but 
results were not convincing. Perico et al. [83] were the 
first to report on two patients undergoing living kidney 
transplantation and receiving an infusion of autologous 
MSCs on post-transplant day 7. Serum creatinine levels 
were increased in MSC-treated patients 7–14 days after 
infusion, suggesting dysfunction of the graft. 1  year 
post-transplantation kidney biopsies showed no signs 
of rejection. Their conclusion was that MSC therapy 
in kidney transplantation is feasible, although timing, 
doses and immunosuppressive medication may need 
to be adapted for optimal effect. Reinders et  al. [84] 
studied the feasibility of autologous MSC administra-
tion in kidney transplantation recipients and showed 
it to be feasible and safe, although the study does not 
allow conclusions on efficacy. Peng et al. [85] combined 
MSCs with a sparing dose of Tacrolimus (50 % of stand-
ard dose) in living-related kidney transplant recipi-
ents. Patients received two infusions of MSCs, the first 
directly into the renal artery at the time of transplan-
tation, the second intravenously 1 month later. Results 
suggest that MSC therapy is safe and could reduce the 
dosage of Tacrolimus. The results of both animal mod-
els and clinical trials are encouraging, but the low num-
ber of randomized controlled trials and small numbers 
of patients make it difficult to draw definitive conclu-
sions and implement MSC therapy in transplantation 
[86].
The knowledge that Tregs have a crucial role in control 
of autoimmunity and tolerance induction in transplanta-
tion has made the induction of-, or infusion of Tregs a 
possible treatment for an array of inflammatory condi-
tions, IRI. In humans, intravenous infusion of Tregs is 
not only feasible and safe, but reduced the incidence of 
graft versus host disease in patients with hematologic 
malignancy that were treated with stem cell transplanta-
tion [87].
Furthermore, after inducing renal IRI in rodents, Tregs 
are able to suppress renal inflammation and preserve 
renal function [88]. In a mouse model, Treg deficiency 
resulted in enhanced renal inflammation, acute tubular 
necrosis and loss of function. Suppletion of Tregs pro-
tected mice from renal dysfunction and improved sur-
vival [89]. Although the use of Tregs as a cellular therapy 
against renal IRI seems promising, studies in humans 
with renal IRI are lacking. The use of Tregs in humans 
is troubled by numerous challenges. The dose of Tregs 
needed for therapeutic efficacy is unclear, the isolation of 
pure Tregs is difficult due to the absence of Treg-specific 
cell surface markers and safety is still a topic of concern 
[90].
Pharmacological treatment
Although many pharmacological agents are effective 
in experimental models of IRI and acute kidney injury, 
none of these have successfully been implemented in 
standard clinical care protocols. With few exceptions, 
most do not enter the clinic. An overview of tested phar-
macological substances is given by Bajwa et  al. [91]. 
Of the eight substances that might reduce inflamma-
tion and reduce cytotoxicity they focused on, only two 
were tested in clinical studies for acute kidney injury 
(statins and erythropoietin). However, in human studies 
the results on renal IRI induced acute kidney injury are 
conflicting. Retrospective case controlled studies found 
that statins reduced acute kidney injury in patients with 
contrast-induced nephropathy [92, 93], whereas a pro-
spective study did not find any beneficial effects [94]. 
Remarkably, a number of observational studies sug-
gested that in the first few weeks and months of starting 
a statin, statins were associated with the early develop-
ment of acute kidney [95]. Due to the adverse data and 
the lack of good prospective randomized controlled tri-
als, there is no evidence that statins reduce the incidence 
of acute kidney injury.
Preconditioning with erythropoietin protects against 
IRI in rodents [96, 97]. Encouraged by these results 
erythropoietin was injected intravenously in humans 
before surgery, and was able to reduce the incidence 
of acute kidney injury in patients who underwent a 
coronary artery bypass [98]. Xin et  al. [99] published 
a meta-analysis including four randomized controlled 
trials that investigated high-dose erythropoietin 
on graft function after kidney transplantation. The 
results showed that high-dose erythropoietin is able 
to reduce the number of patients with DGF, but these 
results did not reach significance. However, Vlacho-
panos et al. [100] published a meta-analysis to explore 
the impact of recombinant human erythropoietin 
on DGF in kidneys from deceased donors. Four ran-
domized controlled trials were included and periop-
erative high-dose recombinant human erythropoietin 
was compared with placebo or no therapy. High-dose 
recombinant human erythropoietin did not affect mor-
tality, acute rejection, DGF or kidney function 4 weeks 
after transplantation. Remarkably, the systolic blood 
pressure was significantly higher in patients treated 
with recombinant human erythropoietin. These results 
question the efficacy and safety of high-dose human 
recombinant erythropoietin in humans. Despite the 
promising results in animal models, translating these 
findings to the clinic is difficult. Variable factors as 
dosage and time points of injection might be a topic of 
interest for further clinical trials.
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Recently, nonerythropoietic peptides derived from 
the three-dimensional structure of erythropoietin 
were shown to exert tissue protective properties. It was 
shown that the helix B surface peptide of erythropoietin 
is responsible for the tissue protective effect of erythro-
poietin and has a much better stability [101]. In a mouse 
renal IRI model, helix B peptide improved renal func-
tion, decreased apoptosis, inflammation and histological 
injury [102]. Yang et al. [103] added the helix B peptide 
to preservation and reperfusion solutions used to normo-
thermically perfuse porcine kidneys after 20 min of warm 
and 18 h of cold ischemia. Adding helix B peptide to the 
reperfusion solution improved the renal blood flow, oxy-
gen consumption and urine output during reperfusion 
and decreased renal tissue damage. Helix B peptide could 
be the key needed to translate the beneficial effects of 
erythropoietin to human transplantation.
MicroRNA’s
MicroRNA’s are RNA-molecules of 20–25 nucleotides 
long. They are capable to inhibit protein transcription 
by stimulating degradation of mRNA [104]. The major-
ity of gene expression is regulated in this way. A promis-
ing quality of microRNA’s is their stability in body fluids 
[105], which makes them a good candidate to act as a 
biomarker or as a therapeutical target.
One microRNA can inhibit more than 100 genes, so 
determining the role of microRNAs in IRI is difficult. 
The few studies on microRNAs in renal IRI failed to elu-
cidate an unequivocal microRNA-signature [106–108]. 
Expression profiling of microRNAs following renal 
IRI in a mouse model showed that nine miRNAs (miR-
21, miR-20a, miR-146a, miR-199a-3p, miR-214, miR-
192, miR-187, miR-805, and miR-194) are differently 
expressed compared to sham animals [108]. In vitro 
studies revealed that miR-21 is expressed in proliferat-
ing tubular epithelial cells, and overexpression of miR-21 
has a protective effect against cell death. This might sug-
gest that miR-21 plays a role in protection against IRI. In 
humans, microRNA expression profiles have been ana-
lysed to see if microRNAs may predict the outcome after 
kidney transplantation [106, 107]. In renal biopsies of 
patients with acute rejection, 20 differentially expressed 
miRNAs were identified [106]. These expression profiles 
may provide useful information about the outcome after 
kidney transplantation. Unfortunately, research so far has 
not brought major insights in the role of microRNAs as 
therapeutic target or agent in both animals and humans 
[109].
Discussion
The improved results after kidney transplantation and 
the increased waiting list have contributed to the growing 
gap between organ demand and supply. Extension of 
the donor pool is needed to diminish this gap. There-
fore, there has been a shift to the use of DCD donors and 
extended criteria donors. DCD donors have an increased 
incidence of DGF compared to DBD donors, while the 
rate of acute rejection is similar in both groups [9, 10]. 
Kidneys from extended criteria donors have a higher 
risk of DGF, lower graft survival and suboptimal kidney 
function [13, 14]. Although renal IRI is inevitable dur-
ing transplantation and has detrimental effects on the 
outcome, there is no therapy available. Therefore, find-
ing a method to ameliorate renal IRI is of major interest. 
Renal IRI can be treated before-, during-, and after trans-
plantation, or a combination thereof. When treatment 
is applied before ischemia, translation of these data is 
difficult since in the human setting, treatment before 
ischemia would imply treatment of the donor. This raises 
ethical concerns in DCD donors [110]. During treat-
ment of the living donors, the donor must give full con-
sent and treatment should not interfere with the donor’s 
health. An option for treatment of the (living) donor 
before transplantation is dietary preconditioning. Van 
Ginhoven et al. [39] showed that dietary pretreatment of 
living donors is feasible and safe, but the robust effects 
on reducing IRI as observed in mice are lacking. Despite 
many experimental studies which show beneficial effects 
on an array of treatments and interventions against IRI, 
translation to humans has not been successful [111]. 
In animal experiments, genetic variability is low and 
mostly young, healthy, males are used. This is obviously 
not representative for the population that is undergo-
ing kidney transplantation and is experiencing renal IRI. 
Overweight, comorbidities, old age, gender and the use 
of medication can all interfere with the effects of stud-
ied methods to ameliorate renal IRI [112, 113]. Another 
limitation of animal experiments may be the use of warm 
ischemia models to mimic transplantation induced IRI 
[30, 31, 71, 74]. The use of cellular therapy is difficult 
to translate to humans due to the differences between 
animals and humans. More clinical trials are needed to 
evaluate the effect of both MSC and Tregs. It would be 
of tremendous value to use MSCs, or to be able to induce 
the production of Tregs in the recipient to ameliorate 
renal IRI. Besides these translational difficulties, another 
problem in the treatment of IRI is its pathophysiological 
complexity. Many pathological mechanisms contribute to 
IRI and can be focused on. Studies on IRI treatment are 
therefore divers, and the probability to find a single ther-
apeutical agent is low. Besides that, experimental thera-
peutical agents may induce adverse side effects [114–117] 
or be carcinogenic [118, 119] which limits their use in 
humans. Another difficulty in translating animal results 
into humans is the publication bias. It is difficult to get 
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an objective overview of the results of experimental 
therapies since there may be a bias towards publication 
of studies with a positive outcome [120]. Nevertheless, 
machine perfusion and (remote) ischemic pre- and post-
conditioning are promising treatment options, which are 
feasible and safe. Especially machine perfusion induces 
beneficial effects on kidney function after transplantation 
in various donor types, and large randomized controlled 
trials are being conducted. The use of machine perfusion 
is actually making the translation to the clinical arena.
Conclusion
Renal IRI is a highly relevant detrimental consequence of 
kidney transplantation and therefore an important topic 
in transplantation research. Studying renal IRI is com-
plex though, coping with translational difficulties, and 
multifactorial pathophysiological mechanisms. Although 
animal studies have resulted in promising methods to 
ameliorate renal IRI, we are still lost in translation since 
only few animal data are finding their way into the clinic 
and improve transplant outcome. This gap in our under-
standing of IRI may be filled in the next years with new 
data derived from more sophisticated animal models and 
results of large randomized controlled trials.
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